WASHINGTON, DC - Energy and Commerce Committee members voted yesterday 54-0 to advance H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017. Throughout the committee process to reauthorize FDA’s user fee programs, there’s been tremendous bipartisan support.
We asked a few committee members why #FDARA is so important. Tune in below to see what they had to say.
